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Abstract: 
This study presents the identification of N-(1-amino-3-methyl-1-oxobutan-
2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide 
that was termed 3,5-AB-CHMFUPPYCA. This compound was obtained from 
a UK-based Internet vendor, who erroneously advertised this ‘research 
chemical’ as AZ-037 and which would have been associated with (S)-N-(1-
amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-5-(4-fluorophenyl)-
1H-pyrazole-3-carboxamide. The presence of the pyrazole core indicates a 
bioisosteric replacement of an indazole ring that is frequently associated 
with synthetic cannabinoids of the “PINACA”, “FUBINACA” and “CHMINACA” 
series. The pyrazole ring system present in 3,5-AB-CHMFUPPYCA gives rise 
to the regioisomer N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (named 
5,3-AB-CHMFUPPYCA) and both isomers were synthesized using two 
specific routes which supported the correct identification of the ‘research 
chemical’ as 3,5-AB-CHMFUPPYCA. Both isomers could be conveniently 
differentiated. Interestingly, a route specific chlorine-containing by-product 
also was observed during the synthesis of 3,5-AB-CHMFUPPYCA and 
identified as N-(1-amino-3-methyl-1-oxobutan-2-yl)-4-chloro-1-
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(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide. An 
extensive analytical characterization included chromatographic, 
spectroscopic, mass spectrometric platforms as well as crystal structure 
analysis. The syntheses and analytical characterizations of both AB-
CHMFUPPYCA isomers are reported for the first time and it serves as a 
reminder that the possibility of mislabeling of ‘research chemicals’ cannot 
be excluded. The pharmacological activities of both AB-CHMFUPPYCA 
isomers remain to be explored.  
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Abstract 
This study presents the identification of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide that was termed 
3,5-AB-CHMFUPPYCA. This compound was obtained from a UK-based Internet 
vendor, who erroneously advertised this ‘research chemical’ as AZ-037 and which 
would have been associated with (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide. The presence of the 
pyrazole core indicates a bioisosteric replacement of an indazole ring that is 
frequently associated with synthetic cannabinoids of the “PINACA”, “FUBINACA” and 
“CHMINACA” series. The pyrazole ring system present in 3,5-AB-CHMFUPPYCA 
gives rise to the regioisomer N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (named 5,3-AB-
CHMFUPPYCA) and both isomers were synthesized using two specific routes which 
supported the correct identification of the ‘research chemical’ as 3,5-AB-
CHMFUPPYCA. Both isomers could be conveniently differentiated. Interestingly, a 
route specific chlorine-containing by-product also was observed during the synthesis 
of 3,5-AB-CHMFUPPYCA and identified as N-(1-amino-3-methyl-1-oxobutan-2-yl)-4-
chloro-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide. An 
extensive analytical characterization included chromatographic, spectroscopic, mass 
spectrometric platforms as well as crystal structure analysis. The syntheses and 
analytical characterizations of both AB-CHMFUPPYCA isomers are reported for the 
first time and it serves as a reminder that the possibility of mislabeling of ‘research 
chemicals’ cannot be excluded. The pharmacological activities of both AB-
CHMFUPPYCA isomers remain to be explored.  
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Introduction 
Over the past decade, the phenomenon linked to new psychoactive substances 
(NPS) has attracted great interest from various communities and stakeholders that 
are concerned with public health, law enforcement and a range of fundamental 
sciences. The diversity of compounds that show, or are suspected to show, 
psychoactive properties in humans and that are made available to the general public 
by various routes include synthetic replacements for controlled substances, designer 
drugs in the traditional sense, regulated and unregulated medicinal products and 
derivatives of various biological activities developed by the pharmaceutical industry.[1] 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is 
currently monitoring over 450 NPS via the European Union (EU) Early warning 
system (EWS) on NPS and it has become clear that the number of notified synthetic 
cannabinoids has risen to over 130.[2,3] The number of substances, the diversity in 
their chemical structure and the rate of their emergence make synthetic cannabinoids 
one of the largest family of NPS monitored at European level and it is equally 
obvious that this is a more widespread phenomenon (e.g.[4,5]). A number of recently 
occurring synthetic cannabinoids included the emergence of substituted indazole 
core structures that carry a valinamide component. Examples may be found in the 
so-called “PINACA”, “FUBINACA” and “CHMINACA” series (Figure 1A) and a range 
of studies have been published[6-20] in addition to recent developments in the United 
States of America where some of these newly emerging substances were subjected 
to temporary placement into Schedule 1.[21,22]  
 
A more recent example in which the indazole core is replaced by a pyrazole ring, 
thus creating a bioisosteric system that mimics the indazole ring system, can be 
found in (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-5-(4-
fluorophenyl)-1H-pyrazole-3-carboxamide that is currently advertised by a number of 
Internet retailers as the synthetic cannabinoid AZ-037. Following previously 
suggested conventions in naming structurally related substances, the name 5,3-5F-
AB-FUPPYCA is suggested (Figure 1B). Although the identification of the structurally 
related 3,5-5F-ADB-FUPPYCA has been recently reported[23] (Figure 1B), detailed 
data on AZ-037 have not yet been described. The present study describes the 
characterization of a sample advertised as AZ-037 that was donated in January 2015 
by an online retailer based in the United Kingdom. This sample was subjected to 
analytical characterization by gas chromatography (GC) and high performance liquid 
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chromatography (HPLC) coupled to various forms of mass spectrometry (MS) and 
nuclear magnetic resonance spectroscopy (NMR). These investigations revealed that 
the material was inconsistent with the structural features associated with AZ-037. 
Instead, the substance was characterized as N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide, which was 
termed 3,5-AB-CHMFUPPYCA. Incidentally, the detection of this compound has just 
been reported to the EMCDDA by members of the EU EWS on NPS, and was 
termed AB-CHMFUPPYCA.[24] Further confirmation was obtained from organic 
synthesis of this substance along with its alternative regioisomer N-(1-amino-3-
methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazole-3-
carboxamide (5,3-AB-CHMFUPPYCA) that arises from presence of the pyrazole core 
structure. Both isomers were synthesized using two specific routes and subjected to 
extensive analytical characterization using chromatographic, spectroscopic, mass 
spectrometric platforms as well as crystal structure analysis. The ‘research chemical’ 
obtained from the Internet vendor was consistent with a compound isolated from 
plant material in Japan where it was termed AB-CHFUPYCA although further 
confirmation by synthesis of the two possible isomers was not obtained.[25]  
 
Experimental 
Reagents and standards 
All reagents and dry solvents used in the syntheses were obtained from Sigma 
Aldrich Ltd. (Arklow, Ireland). LC-MS grade solvents were obtained from Fisher 
Scientific (Dublin, Ireland). A sample, advertised as AZ-037, was donated by a UK 
based ‘research chemical’ vendor in January 2015. 
 
Syntheses 
Methyl 4-(4-fluorophenyl)-2,4-dioxobutanoate 
Potassium tert-butoxide (11.20 g, 100 mmol) was added to a solution of dimethyl 
oxalate (11.80 g, 100 mmol) in tetrahydrofuran (75 mL). The mixture was stirred at 
room temperature for 30 min. A solution of 4-fluoroacetophenone (6.4 g, 50 mmol) in 
tetrahydrofuran (25 mL) was added and stirring was continued for 1 h. The reaction 
mixture was then added to 0.5 M aqueous hydrochloric acid (600 mL) and the 
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precipitated solid was collected by filtration to afford a light yellow solid (9.54 g, 43 
mmol, 86 %):  ESI-HRMS m/z found 225.0568 (m/z theor. for M+H, C11H10O4F, 
225.0558). 1H NMR (d6-CDCl3) δ 7.77-7.69 (m, 2H, 2 x Ar-CH), 7.23-7.14 (m, 2H, 2 x 
Ar-CH), 7.05 (s, 1H, OH), 3.96 (d, J = 1.2 Hz, 3H), 13C NMR (d6-CDCl3) δ 189.71 
(C=O), 168.67-167.05 (Ar-CF), 165.35 (C(OH)), 162.53 (C=O), 131.27 (Ar-C), 130.50 
(Ar-CH), 116.34 (Ar-CH), 53.20 (CH3), 
19F (d6-CDCl3) δ –103.91 ppm. 
 
Methyl 5-(4-fluorophenyl)-1H-pyrazole-3-carboxylate 
A mixture of methyl 4-(4-fluorophenyl)-2,4-dioxobutanoate (4.48 g, 20 mmol) and 
hydrazine hydrate (1.10 g, 22 mmol) in acetic acid (20 mL) was heated (oil bath at 
100 oC) for 2 h. The mixture was allowed to cool to room temperature and the 
product was collected by filtration to afford colorless crystals that were used without 
further purification (3.08 g, 14.0 mmol, 70 %): ESI-HRMS m/z found 221.0725 (m/z 
theor. for M+H, C11H10O2N2F, 221.0721).  
 
Cyclohexylmethyl)hydrazine trifluoroacetate salt  
A mixture of tert-butyl carbazate (5.89 g, 44.6 mmol) and 
cyclohexanecarboxaldehyde (5.00 g, 44.6 mmol) in methanol (140 mL) was stirred at 
room temperature for 1 h. The solution was then evaporated to dryness. Aqueous 
50 % v/v aqueous acetic acid (125 mL) was added and, with constant mixing, sodium 
cyanoborohydride (2.80 g, 44.6 mmol) was added. The mixture was stirred for 2 h at 
room temperature, diluted with water, neutralized with sodium hydroxide and 
extracted with dichloromethane. Drying (anhydrous magnesium sulfate) and removal 
of the solvent afforded a colorless oil, which was dissolved in a mixture of 
dichloromethane (30 mL) and trifluoroacetic acid (30 mL). The mixture was stirred for 
1 h at room temperature and the volatiles were removed under vacuum to afford a 
light brown, viscous oil (15.27 g which was used without further purification). 
 
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-
pyrazole-3-carboxamide and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (5,3-AB-
CHMFUPPYCA) (Figure 2A) 
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A mixture of crude cyclohexylmethyl)hydrazine trifluoroacetate (2.00 g) and methyl 4-
(4-fluorophenyl)-2,4-dioxobutanoate (1.12 g, 10 mmol) in methanol (20 mL) was 
refluxed for 3 h. The mixture was allowed to cool to room temperature, the volatiles 
removed under vacuum and the residue partitioned between aqueous sodium 
carbonate and dichloromethane. Drying (anhydrous magnesium sulfate) followed by 
solvent removal gave a yellow oil. Tetrahydrofuran (20 mL), water (10 mL) and 
lithium hydroxide (2.00 g) were added. The mixture was heated (oil bath at 80 oC) for 
2 h and then allowed to stir overnight at room temperature. The mixture was diluted 
with water, washed with diethyl ether, made acidic (concentrated aqueous 
hydrochloric acid) and extracted with dichloromethane. Drying (anhydrous 
magnesium sulfate) and removal of the solvent afforded light a light yellow solid (936 
mg). Thionyl chloride (5 mL) was added to the solid (836 mg) and the mixture was 
refluxed for 1 hr. The volatiles were then removed under vacuum. N,N-
Dimethylformamide (5 mL), L-valinamide hydrochloride (0.50 g, 3.3 mmol) and N,N-
diisopropylethylamine (3 mL) were added, and the mixture was stirred at room 
temperature for 4 h. The mixture was diluted with water and extracted with 
dichloromethane. Drying (anhydrous magnesium sulfate) and removal of the solvent 
afforded a light a brown oil (689 mg). This was purified by preparative thin layer 
chromatography (silica gel; ethyl acetate/hexane, 9/1; 2 runs) to afford a beige solid 
(74 mg, 0.19 mmol, 2.1 % from methyl 4-(4-fluorophenyl)-2,4-dioxobutanoate): ESI-
HRMS m/z found 401.2346 (m/z theor. for M+H, C22H30O2N4F, 401.2347); Melting 
point: 58-62 oC. 1H NMR (d6-DMSO) δ 7.63 (s; 1 H; one H from NH2), 7.82-7.85 (m; 3 
H; Ar H and one H from NH2), 7.36 (t; J = 8.8 Hz; 2 H; Ar H), 6.73 (s; 1 H; pyrazole H), 
4.36 (dd; J = 9.0, 6.3 Hz; NH-CH-CO), 4.02 (d; J = 7.2 Hz; 2 H; CyCH2N), 2.03-2.10 
(m; 1 H; CH(CH3)2), 1.71-1.79 (m; 1 H; cyclohexyl H), 1.49-1.59 (m; 3 H; cyclohexyl 
H), 1.34-1.42 (m; 2 H; cyclohexyl H), 1.02-1.14 (m; 3 H; cyclohexyl H), 0.92 (d; J = 
6.8 Hz; 3 H; CH3), 0.88 (d; J = 6.8 Hz; 3 H; CH3) and 0.70-0.8 (m; 2 H; cyclohexyl H) 
ppm; 13C NMR (d6-DMSO) δ 172.54 (C=O), 162.26 (d; 
1JCF = 245 Hz; Ar C), 160.63 
(C=O), 144.95 (pyrazole C), 144.21 (pyrazole C), 131.23 (d; 3JCF = 8 Hz; Ar CH), 
126.19 (Ar C), 115.86 (d; 2JCF = 22 Hz; Ar CH), 106.31 (pyrazole CH), 56.78 (CO-CH-
NH), 55.34 (CyCH2N), 38.09 (cyclohexyl CH), 30.53 (CH(CH3)2), 29.72/29.67 (2 x 
cyclohexyl CH2), 25.67 (cyclohexyl CH2), 24.98/24.95 (2 x cyclohexyl CH2), 19.29 
(CH3) and 17.92 (CH3) ppm; 
19F NMR (d6-DMSO) δ –112.98 ppm. 
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-
pyrazole-3-carboxamide and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
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(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-
CHMFUPPYCA) (Figure 2B) 
A mixture of methyl 5-(4-fluorophenyl)-1H-pyrazole-3-carboxylate (250 mg, 1.14 
mmol), (bromomethyl)cyclohexane (404 mg, 2.28 mmol),  cesium carbonate (371 mg,  
2.28 mmol) in dimethylformamide (3 mL) was stirred overnight at room temperature. 
The mixture was then diluted with saturated aqueous ammonium chloride solution 
and extracted with dichloromethane. Drying (anhydrous magnesium sulfate) and 
removal of the solvent afforded a colorless oil (428 mg). Lithium hydroxide (480 mg) 
and tetrahydrofuran (5 mL) were added, the mixture refluxed for 6 h and then allowed 
to stir overnight at room temperature. The mixture was diluted with water, washed 
with diethyl ether, made acidic  (conc. aqueous hydrochloric acid) and extracted with 
dichloromethane. Drying (anhydrous magnesium sulfate) and removal of the solvent 
afforded light a colorless solid (230 mg, 0.76 mmol). Thionyl chloride (3 mL) was 
added to the solid and the mixture was refluxed for 1 h. The volatiles were then 
removed under vacuum. N,N-Dimethylformamide (2.5 mL), L-valinamide 
hydrochloride (304 mg, 2 mmol) and N,N-diisopropylethylamine (1 mL) were added, 
and the mixture was stirred at room temperature for 4 h. This was then diluted with 
water and extracted with dichloromethane. Drying (anhydrous magnesium sulfate) 
and removal of the solvent afforded a beige solid (257 mg). This was purified by 
preparative thin layer chromatography (silica gel; ethyl acetate/hexane, 9/1) to afford 
an almost colorless solid (115 mg, 0.29 mmol, 25 % from methyl 5-(4-fluorophenyl)-
1H-pyrazole-3-carboxylate). This was recrystallized (ethanol) to give a colorless solid 
(49 mg): ESI-HRMS m/z found 401.2344 (m/z theor. for M+H, C22H30O2N4F, 
401.2347); Melting point: 172-178 oC. 1H NMR (d6-DMSO) δ 8.20 (d; J  = 8.8 Hz; 1 H; 
NH), 7.82-7.85 (m; 2 H; Ar H), 7.48 (s; 1 H; one H from NH2), 7.40 (s; 1 H; pyrazole 
H), 7.27 (tr; J = 8.9 Hz; 2 H; Ar H), 7.13 (s; 1 H; one H from NH2), 4.37 (dd; J = 7.2, 
2.4 Hz; 2 H; CyCH2N), 4.26 (dd; J = 8.4, 8.1 Hz; NH-CH-CO), 2.07-2.14 (m; 1 H; 
CH(CH3)2), 1.77-1.85 (m; 1 H; cyclohexyl H), 1.47-1.67 (m; 5 H; cyclohexyl H), 1.10-
1.17 (m; 3 H; cyclohexyl H) and 0.91-0.99 (m; 8 H; 2 cyclohexyl H and 2 CH3) ppm; 
13C NMR (d6-DMSO) δ 172.87 (C=O), 161.10 (d; 
1JCF = 243 Hz; Ar C), 159.71 (C=O), 
147.62 (pyrazole C), 137.40 (pyrazole C), 129.64 (Ar C), 127.27 (d; 3JCF = 8 Hz; Ar 
CH), 115.96 (d; 2JCF = 21 Hz; Ar CH), 104.84 (pyrazole CH), 58.49 (CO-CH-NH), 
56.47 (CyCH2N), 39.94 (cyclohexyl CH), 30.35 (CH(CH3)2), 30.23 (cyclohexyl CH2), 
26.19 (cyclohexyl CH2), 25.50 (cyclohexyl CH2), 19.68 (CH3) and 18.73 (CH3) ppm; 
19F NMR (d6-DMSO) δ –115.00 ppm. A sample of the product was recrystallized from 
ethyl acetate/cyclohexane for x-ray crystallography. 
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Instrumentation 
 
Liquid chromatography - mass spectrometry 
LC-MS analyses, equipped with an electrospray ionization source, were performed 
on an Agilent 1100 LC system. The column (Allure PFP Propyl, 5 µm, 50 × 2.1 
mm) was from Restek (Bellefonte, PA, USA) and the aqueous mobile phase A 
consisted of 0.1% formic acid in water whereas mobile phase B was prepared from 
0.1% formic acid in acetonitrile, respectively. The Agilent LC-MSD settings 
were as follows: positive electrospray mode, capillary voltage 3000 V, drying 
gas (N2) 12 L/min at 350 °C, nebulizer gas (N2) pressure 60 psi, m/z 50-500, 
fragmentor voltage either 50 V, 130 V or 150 V. Samples for LC-MS analysis (2 
µL injection volume) were dissolved in acetonitrile/water (1:1, containing 0.1% 
formic acid) at a concentration of 5 µg/mL. The following gradient elution program 
was used: 0-5 min 12% A and then increased to 35% over 30 min using a linear 
gradient. The flow rate was 1 mL/min and the column temperature was 30 °C. 
 
Gas chromatography – mass spectrometry 
An Agilent 6980 GC coupled to an Agilent 5973 MSD (HP-5ms column, 30 m x 0.25 
mm x 0.25 µm) using helium as the carrier gas at a constant flow of 1 mL/min was 
employed in splitless mode. Injection port and transfer line temperatures were set at 
250 oC and 280 oC, respectively. Oven temperature: 150 oC held for 2 min, ramped 
at 20 oC/min to 300 oC and held for 10.5 min. The total run time was 20 min. The 
samples for analysis were dissolved in acetonitrile and the injection volume was 1 
µL. 
 
X-Ray Crystallography 
Intensity data were collected at 100(2) K using a MiTeGen micromount on a Bruker 
APEX Duo CCD diffractometer equipped with an Oxford Cobra cryosystem. Data 
were collected using ω and ϕ scans, corrected for Lorentz and polarization effects, 
and integrated using the Bruker APEX program suite. Structures were solved by 
direct methods and refined with least squares procedures. All non-hydrogen atoms 
were refined anisotropically and hydrogen atoms were placed geometrically in the 
calculated positions using a riding model except for H21, H28a, and H28b which 
were located and refined.  
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Data collected using Cu Kα radiation (1.54178 Å) for a colorless plate crystal 0.26 × 
0.11 × 0.08mm3, C24H32FN5O2, M = 441.54, Monoclinic, P21, a = 12.1979(5), 
b=7.0566(3), c = 14.6230(6)Å, β = 111.6180(10)°, V = 1170.15(8)Å3, Z=2, ρ = 
1.253mg/m3, µ =0.709mm-1, Reflections collected 18953 (θmax = 68.49°), independent 
reflections 4247, R(int) = 0.0321, S = 1.025, R1 = 0.0290, wR2 = 0.0753.* CCDC 
deposition number 1405051. (* R1=Σ||Fo|-|Fc|| / Σ |Fo| and wR2 = Σw(|Fo|2-|Fc|2)2 / 
Σw|Fo|2)1/2) 
 
Nuclear magnetic resonance spectroscopy 
Samples were prepared in d6-DMSO and 
1H (600 MHz) and 13C (150 MHz) NMR 
spectra were recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI 
cryoprobe. 1H NMR spectra were referenced to an external TMS reference at δ = 0 
ppm. 
 
High-resolution electrospray mass spectrometry 
HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap 
Discovery (Thermo Fisher, UK). Samples were dissolved in acetonitrile/water 
(1:1, containing 0.1% formic acid) and infused at a rate of 5 µL/min. Full 
accurate high-resolution (30000) mass scans were performed in positive 
electrospray mode. Measured accurate masses were within ± 5ppm of the 
theoretical masses. The following conditions were used: drying gas (N2) 10000 
mL/min, capillary temperature 310 °C, spray voltage 4 V, capillary voltage 22 V and 
tube lens 77 V. 
 
Results and discussion 
 
The structural diversity associated with substances considered as so-called 
synthetic cannabinoids can create challenges to forensic, clinical, law enforcement 
and regulatory communities.[2-5,26-28] Some of the recently occurring indazole 
derivatives (Figure 1A) are based on the patent literature which point towards 
appreciable CB1 receptor affinity and [
35S]GTPγS activity[29,30] but others remain to 
be fully explored to assess the extent to which these substances show 
psychopharmacological similarities to compounds present in cannabis. A compound 
that appeared to deviate from currently reported core structures, i.e. carrying a 
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pyrazole moiety instead of a more established indole, benzimidazole, pyrrole or 
indazole core, has been advertised on a number of ‘research chemicals’ websites 
as AZ-037, which represents (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (Figure 1B). Any 
information about its psychoactive or pharmacological properties seems to be 
currently unavailable although it appears to be advertised as a synthetic 
cannabinoid on various websites. The EMCDDA has recently received a notification 
on its detection in an EU Member State via the EU EWS on NPS.[31]  
 
The present investigation was initiated following the donation of a vendor sample to 
the authors’ laboratories labeled as AZ-037. During initial characterization it was 
revealed that the analytical data were inconsistent with the expected structure. 
Inspection of the UK-based website also indicated that the suggested IUPAC name 
for AZ-037 was also not in agreement with the shown structure. The shown 
structure associated with AZ-037 was 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 
8-quinolinyl ester, i.e. commonly referred to as the synthetic cannabinoid 5F-PB-22. 
Interestingly, the analytical characterization of a substance very closely related to 
AZ-037 has been published recently. In this case, the reported compound was N-
(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-
pyrazole-5-carboxamide and the suggested name for this substance is 3,5-5F-ADB-
FUPPYCA (Figure 1B). The presence of the pyrazole ring can give rise to a number 
of isomers, which complicates matters significantly and this meant that the 
chromatographic separation and characterization of isomers was deemed 
necessary. The preparation of both isomers associated with positions 5 and 3 
confirmed unambiguously that the sample received from the Internet supplier was 
consistent with 3,5-AB-CHMFUPPYCA (Figure 2). 
 
Synthesis 
 
Both regioisomers 5,3-AB-CHMFUPPYCA and 3,5-AB-CHMFUPPYCA were 
synthesized using two specific routes that are outlined in Figure 2. The synthesis of 
5,3-AB-CHMFUPPYCA involved the reaction of methyl 4-(4-fluorophenyl)-2,4-
dioxobutanoate (a) with (cyclohexylmethyl)-hydrazine (b), which gave rise to the 
pyrazole intermediate (c). This intermediate was then reacted with lithium 
hydroxide, which provided the carboxylic acid species (d). This entity was reacted 
with thionyl chloride and subsequently N,N-dimethylformamide, L-valinamide 
hydrochloride and N,N-diisopropylethylamine to yield the 5,3-AB-CHMFUPPYCA  
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product (Figure 2A). The preparation of 3,5-AB-CHMFUPPYCA involved reacting 5-
(4-fluorophenyl)-1H-pyrazole-3-carboxylate (e) with (bromomethyl)-cyclohexane (f) 
and cesium carbonate yielding the cyclohexylmethyl intermediate (g). This 
intermediate was reacted with lithium hydroxide, which induced the formation of the 
carboxylic acid species (h). This entity was reacted with thionyl chloride and 
subsequently N,N-dimethylformamide, L-valinamide hydrochloride and N,N-
diisopropylethylamine, which yielded the 3,5-AB-CHMFUPPYCA  product  (Figure 
2B). 
 
The structural differences in the regioisomers included the positioning of the 
substituents around the pyrazole core, which were dictated by the positioning of the 
double bonds within the pyrazole ring structure. In the 5,3-AB-CHMFUPPYCA isomer 
(Figure 2A) the 4-fluorophenyl component was attached to position 5 whereas the 
secondary carboxamide structure was attached to position 3 of the pyrazole ring. In 
case of the 3,5-AB-CHMFUPPYCA isomer, the opposite arrangement was present. A 
route specific chlorine containing by-product, N-(1-amino-3-methyl-1-oxobutan-2-yl)-
4-chloro-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide, was 
encountered during the synthesis of the 3,5-AB-CHMFUPPYCA isomer 
(supplemental information) and this was not observed during the preparation of the 
regioisomeric form. 
 
Gas chromatography mass spectrometry 
Separation of both isomers was successfully achieved using gas chromatography 
(GC). The retention times for 5,3-AB-CHMFUPPYCA and 3,5-AB-CHMFUPPYCA 
were 14.74 and 15.20 min, respectively, and a comparison with the vendor sample 
was in agreement with the identity of the latter (Figure 3A-C). A comparison of both 
EI mass spectra also provided sufficient evidence that both isomers could be 
differentiated based on fragmentation patters (Figure 3E-F). In the EI mass spectrum 
for 5,3-AB-CHMFUPPYCA, the base peak was observed at m/z 285 and indicated 
the loss of 115 Da from the parent molecule, which represented the formation of an 
oxonium species (Figure 3G). Another dominant peak was observed at m/z 356 that 
may be described by the loss of formamide from the molecular ion. Another minor 
fragment encountered in the EI mass spectrum was m/z 189, which might have been 
consistent with the loss of cyclohexylmethyl species from the oxonium ion at m/z 285. 
In the EI mass spectrum of 3,5-AB-CHMFUPPYCA, the base peak was observed at 
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m/z 257, which was thought to represent the 1-(cyclohexylmethyl)-3-(4-fluorophenyl)-
1H-pyrazole fragment and its formation might have been facilitated by the position of 
the double bonds within the pyrazole ring of the 3,5-AB-CHMFUPPYCA isomer 
(Figure 3G). The positioning of the double bonds in the pyrazole ring might have 
facilitated the formation of a temporary double bond between the nitrogen at position 
1 of the pyrazole ring and the carbon at position 5, which might have resulted in the 
formation of a thermodynamically stable species (Figure 4). The formation of this 
species would not have been possible with the 5,3-AB-CHMFUPPYCA isomer due to 
the positioning of the double bonds within the pyrazole ring. Also present in the EI 
mass spectrum of the 3,5-AB-CHMFUPPYCA isomer was the detection of the 
molecular ion at m/z 400. The fragment at m/z 356 was presumably formed by the 
loss of formamide (Figure 3G). The chlorinated by-product formed during the 
synthesis of 3,5-AB-CHMFUPPYCA was detected under GC-MS analysis conditions 
and a retention time of 16.07 min was obtained for this compound (supplemental 
data). 
 
Liquid chromatography mass spectrometry 
Analysis of both synthesized isomers and the vendor sample by high performance 
liquid chromatography (HPLC) confirmed satisfactory separation. A retention time of 
13.41 min was obtained for the 5,3-AB-CHMFUPPYCA isomer, whereas a retention 
time of 13.85 min was obtained for the 3,5-AB-CHMFUPPYCA isomer (Figure 5). 
The electrospray ionization (ESI) single quadrupole mass spectra obtained from in-
source collision-induced dissociation (CID) of the synthesized regioisomers (150 V 
fragmentor voltage) shared similar product ions but key features that allowed for 
differentiation between the two substances were also apparent (Figure 6). For 
example, the in-source CID spectrum of 5,3-AB-CHMFUPPYCA displayed the 
sodiated adduct [M + Na]+ at m/z 423 as the base peak (Figure 6A), which was not 
the case with 3,5-AB-CHMFUPPYCA where the relative abundance was around 40% 
(Figure 6B). A major difference, however, was observed in the mass spectrum of 3,5-
AB-CHMFUPPYCA that formed a base peak at m/z 260 and which was absent in the 
5,3-AB-CHMFUPPYCA (Figure 6A). Figure 6C shows a proposed mechanism of its 
formation that may be rationalized by the loss of 2-cyclohexylacetamide from the 
protonated molecule. Product ions common in both spectra included m/z 356 by way 
of cleaving formamide from the protonated molecule and the subsequent formation of 
the m/z 285 oxonium ion. The m/z 189 ion may have then been formed by the loss of 
the cyclohexylmethyl species from the oxonium fragment, resulting in a species with 
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chemical formula C10H6FN2O
+. The chlorinated by-product was observed during the 
HPLC-ESI-MS analysis of 3,5-AB-CHMFUPPYCA. A retention time of 14.49 min was 
obtained for this compound (supplemental data). Analysis by high-resolution mass 
spectrometry was employed, which yielded formation of identical product ions for 
each isomer (supplemental data). 
 
Nuclear magnetic resonance spectrometry 
In addition to one-dimensional proton (1H), carbon (13C) and fluorine (19F) NMR 
analyses, the implementation of two-dimensional experiments proved helpful for the 
characterization of both isomers and the vendor sample. For example, in the case of 
5,3-AB-CHMFUPPYCA, heteronuclear multiple-bond correlation (HMBC) 
experiments revealed a 3-bond 1H/13C correlation between the respective carbon 
atom at position 5 of the pyrazole ring and the protons at the ortho position of the 
fluorinated phenyl ring. A correlation was also observed between the aforementioned 
carbon and the protons of the methylene group attached to the cyclohexyl ring 
(Figure 7A). As far as 3,5-AB-CHMFUPPYCA was concerned, the 3-bond correlation 
between the carbon atom at position 5 of the pyrazole ring and the protons on the 
methylene group attached to the cyclohexyl ring (Figure 7B) was also present. As 
expected, the 3-bond correlation with the protons on the fluorinated phenyl ring was 
not detected. The vendor sample was also subjected to HMBC analysis and 
confirmed the 3,5-AB-CHMFUPPYCA assignment (supplemental data). Further 
information was obtained from nuclear Overhauser effect spectroscopy (NOESY), 
which provided additional insights into distinguishing features between the two 
isomers. A qualitative nuclear Overhauser experiment (NOE) showed connectivity 
between the methylene group attached to the cyclohexyl ring and the protons 
attached to the ortho position of the fluorinated phenyl ring present in the 5,3-AB-
CHMFUPPYCA isomer. This nOe was not observed with 3,5-AB-CHMFUPPYCA 
(supplemental data).  
 
X-Ray crystallography 
The solid-state structure of the 3,5-AB-CHMFUPPYCA isomer was elucidated by 
single crystal X-ray diffraction and is shown below in Figure 8. The structure is a 
solvate with a co-crystallized molecule of acetonitrile present in the asymmetric unit. 
The molecule crystallizes in the chiral monoclinic space group P21 and the chiral 
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center C22 has been determined to be the S-enantiomer. The packing is dominated 
by the amide donor groups (N21, N28), which form hydrogen bonds with the terminal 
amido oxygen O27 (N28cO27 range 2.856(2) - 2.963(2) Å). These link the 
molecules into a strongly associated chain. A channel exists between the chains and 
the acetonitrile solvent molecules lies within it. A weak NHcN interaction (N28cN29, 
3.039 Å) exists between 3,5-AB-CHMFUPPYCA and the solvent (supplemental 
information). 
 
Conclusion 
An in-depth analytical characterization of a ‘research chemical’ advertised as AZ-037 
revealed mislabeling when it transpired that it was consistent with 3,5-AB-
CHMFUPPYCA instead. The combination of analytical techniques and confirmation 
of compound identification by organic synthesis provided an effective approach to 
tackling an increasingly complex area of investigation where increasing demands are 
placed on investigators in the field of new psychoactive substances.   
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Figures 
Figure 1. Chemical structures of synthetic cannabinoids from (A) the PINACA, 
FUBINACA, CHMINACA series and (B) the FUPPYCA series. 
Figure 2.  Synthesis protocol for the AB-CHMFUPPYCA isomers. (A) Specific 
synthetic route for 5,3-AB-CHMFUPPYCA. (B) Specific synthetic route for 3,5-AB-
CHMFUPPYCA. 
 
Figure 3. (A-F) GC-MS data obtained for both AB-CHMFUPPYCA isomers and 
vendor sample. (G) Proposed EI-MS fragmentation patterns for the AB-
CHMFUPPYCA isomers. 
Figure 4. Proposed mechanism for the formation of 1-(cyclohexylmethyl)-3-(4-
fluorophenyl)-1H-pyrazole species observed at m/z 257 in the EI-mass spectrum of 
3,5-AB-CHMFUPPYCA. 
Figure 5. (A-F) Analysis of synthesized AB-CHMFUPPYCA isomers and vendor 
sample using high performance liquid chromatography selected ion monitoring (SIM) 
mass spectrometry at 50V. 
 
Figure 6. (A-B) Electrospray ionization single quadrupole mass spectra following in-
source collision-induced dissociation at 150 V. (C) Proposed mechanism for the 
formation of the species with m/z 260 that may be rationalized by the loss of 2-
cyclohexylacetamide from the protonated molecule. 
Figure 7. Heteronuclear multiple-bond correlation NMR spectra for (A) the 5,3-AB-
CHMFUPPYCA isomer and (B) the 3,5-AB-CHMFUPPYCA isomer. 
Figure 8. Molecular structure of 3,5-AB-CHMFUPPYCA (thermal displacement at 
50% probability) with hydrogen atoms omitted for clarity. 
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Chemical structures of synthetic cannabinoids from (A) the PINACA, FUBINACA, CHMINACA series and (B) 
the FUPPYCA series.  
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Synthesis protocol for the AB-CHMFUPPYCA isomers. (A) Specific synthetic route for 5,3-AB-CHMFUPPYCA. 
(B) Specific synthetic route for 3,5-AB-CHMFUPPYCA.  
142x101mm (300 x 300 DPI)  
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(A-F) GC-MS data obtained for both AB-CHMFUPPYCA isomers and vendor sample. (G) Proposed EI-MS 
fragmentation patterns for the AB-CHMFUPPYCA isomers.  
288x401mm (300 x 300 DPI)  
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Proposed mechanism for the formation of 1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole species 
observed at m/z 257 in the EI-mass spectrum of 3,5-AB-CHMFUPPYCA.  
66x24mm (300 x 300 DPI)  
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(A-F) Analysis of synthesized AB-CHMFUPPYCA isomers and vendor sample using high performance liquid 
chromatography selected ion monitoring (SIM) mass spectrometry at 50V.  
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(A-B) Electrospray ionization single quadrupole mass spectra following in-source collision-induced 
dissociation at 150 V. (C) Proposed mechanism for the formation of the species with m/z 260 that may be 
rationalized by the loss of 2-cyclohexylacetamide from the protonated molecule.  
215x294mm (300 x 300 DPI)  
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Heteronuclear multiple-bond correlation NMR spectra for (A) the 5,3-AB-CHMFUPPYCA isomer and (B) the 
3,5-AB-CHMFUPPYCA isomer.  
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Molecular structure of 3,5-AB-CHMFUPPYCA (thermal displacement at 50% probability) with hydrogen atoms 
omitted for clarity.  
159x168mm (96 x 96 DPI)  
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